← IMCR: big moves and long-term fundamentals中文

Immunocore: The Long View

What the filings say about its story, dilution and cash runway.

Last updated Nov 12, 2026 · Reflects: 10-K FY2025, the 10-Q for Q3 2026 and the Q3 release (Nov 6, 2026)

Disclosure: one or more of our editors own shares of Immunocore (IMCR) as a long-term investment. This page is information, not investment advice.

Sources used most:

1. In one paragraph

Last updated Nov 12, 2026. Reflects the 10-K FY2025, the 10-Q for Q3 2026 and the Q3 release (Nov 6, 2026).

Immunocore, based in Oxfordshire, UK, gets all of its revenue from one drug, Kimmtrak ($400.0M of net sales in 2025, +29%; $324.8M in the first nine months of 2026, +10%), and has two Phase 3 trials of Kimmtrak, TEBE-AM and ATOM, and one of brenetafusp with nivolumab, PRISM-MEL-301.

  • Platform: bispecific T-cell receptor medicines on its “ImmTAX” platform. Its cancer drugs recognise fragments of proteins from inside tumour cells that are displayed on the cell surface, and redirect the patient’s own T cells to kill those cells; its autoimmune candidates instead aim to suppress T-cell activity in selected tissues.
  • Product: Kimmtrak (tebentafusp), approved in 2022 for metastatic uveal melanoma (an eye cancer that spreads, mostly to the liver) in patients with the tissue type HLA-A*02:01. It is approved in 39 countries and launched in over 30.
  • 2025 net sales were $400.0M (+29%): United States $257.0M (64%), Europe $131.4M (33%) and international $11.6M (3%) (our calculation)1. In Q3 2026, net sales were $102.2M: United States $62.2M, Europe $34.9M and international $5.1M (Q3 release). The company reports one segment.
  • Cost of revenue was under 1% of sales in the first nine months of 2026 (our calculation)2. Contract manufacturers in Denmark and Germany make the drug (named in section 6).
  • Pipeline: three Phase 3 trials in melanoma (TEBE-AM, PRISM-MEL-301 and ATOM) and earlier programmes in other cancers, HIV and autoimmune disease. TEBE-AM’s topline overall survival data are expected in Q2 2027, and a randomized Phase 2/3 trial of Kimmtrak with brenetafusp, DUET-UVEAL, is planned (Q3 release).
  • It had 524 full-time employees at Dec 31, 2025.

Sources: 10-K FY2025 (revenue by region, manufacturing, employees); Q3 2026 release (approvals, launches, Q3 sales); 10-Q Q3 2026.

2. Story so far

Last updated Nov 12, 2026. Reflects filings through Nov 6, 2026.

In short: Immunocore listed on Nasdaq in 2021 and won approval for Kimmtrak in 2022, the first drug its platform produced. Sales grew every year to $400.0M in 2025, enough for the company to report net income in the first half of 2026, while it spent the rest on research and on three Phase 3 trials. It funded this with a 2022 share sale and $402.5M of convertible notes (debt that can be exchanged for shares) in 2024, with no later share offering reported through Sep 30, 2026 (employee option exercises brought in $20.9M in the first nine months of 2026). The next test is the TEBE-AM trial in skin melanoma, fully enrolled in September 2026, whose topline results are now expected in Q2 2027.

Date Milestone Source
Feb 2021 Lists American depositary shares (ADSs) on Nasdaq at $26.00 each; the IPO and a concurrent private placement raised $286.9M net 10-K FY2023
2022 ★ The FDA and the European Commission approve Kimmtrak for HLA-A*02:01-positive metastatic uveal melanoma 10-K FY2023
Jul 2022 Sells 3,733,333 shares (ADSs and non-voting shares) at $37.50 each in a private placement; $139.5M net 10-K FY2023, equity note
Nov 2022 Signs a loan agreement with Pharmakon for up to $100M; draws $50M 10-K FY2025, note 7
Feb 2024 ★ Sells $402.5M of 2.50% convertible notes due Feb 1, 2030; BMS agrees to supply nivolumab for the PRISM-MEL-301 trial at no cost 10-K FY2025
Nov 8, 2024 Repays the Pharmakon loan in full 10-K FY2025
2025 New pricing agreements in Germany and France; Immunocore disputes one element of the French agreement relating to prior periods 10-K FY2025
Jun 2025 Recalls one Kimmtrak batch worldwide after an unexpected result in routine stability testing; no material financial impact expected 10-K FY2025
Feb 25, 2026 2025 results: Kimmtrak sales $400.0M (+29%); “moderating revenue growth” expected in 2026 Q4 2025 release
Jan 27, 2026 Head of research and development (R&D) David Berman resigns (effective Feb 27); the company will not seek a direct replacement 8-K, Jan 30, 2026
Apr 2026 Five-year survival data at AACR: 16% of patients on Kimmtrak alive vs 8% in the control arm (hazard ratio 0.67, an estimated 33% lower risk of death over the follow-up) Q1 2026 release
Aug 6, 2026 First-half net income of $12.2M; TEBE-AM topline (first main results) now “as early as the end of 2026” (earlier: “as early as 2H 2026”) Q2 2026 release
Sep 14, 2026 ★ TEBE-AM reaches its target enrolment of 540 patients 8-K release
Oct 28, 2026 Our coverage starts with this Long View —
Nov 6, 2026 ★ Q3: Kimmtrak sales $102.2M, down 1% year on year (about +10% on Immunocore’s own adjustment); TEBE-AM topline now Q2 2027; DUET-UVEAL Phase 2/3 planned Q3 release

3. Latest quarter: did the story change?

Last updated Nov 12, 2026. Reflects Q3 2026 (quarter to Sep 30, 2026), the Q3 release and the 10-Q (Nov 6, 2026). The release mentions no earnings call.

Bottom line: Kimmtrak sales fell 12% from Q2 (our calculation)3 after Q2’s wholesaler stocking; Immunocore puts underlying year-on-year growth at about 10%, which we can’t reproduce from its disclosures. TEBE-AM topline moved to Q2 2027 from “as early as the end of 2026”. A Phase 2/3 combination trial is planned, and about $120M of rebate payments are expected in Q4.

Driver Last quarter → this quarter Management: before → now Signal
Kimmtrak net sales Q2 $115.9M → Q3 $102.2M (−1% year on year); US $74.9M → $62.2M; Europe $34.1M → $34.9M; international $6.9M → $5.1M “Moderating revenue growth” for 2026, no numeric guide → underlying growth of about 10% on its own adjustment, which removes Q2’s US wholesaler stocking and an extra week of US sales in Q3 2025 Worse
TEBE-AM Target enrolment of 540 reached (Sep 14) → enrolment complete Topline “as early as the end of 2026” (Aug 6, Sep 14) → Q2 2027; the trial is event-driven; no reason given for the change Worse
Brenetafusp Monotherapy data → combination with Kimmtrak: 29% response rate and 70% two-year survival in 17 evaluable first-line patients (company figures; no control group) No disclosed randomized plan for this combination in uveal melanoma → DUET-UVEAL, a randomized Phase 2/3 trial, planned; no start date disclosed Watch
Net result Q2 −$0.8M → Q3 −$14.2M First-half net income $12.2M → nine-month net loss $2.1M Worse
Cash and rebate payments Cash and marketable securities $880.2M (Jun 30) → $901.3M (Sep 30) About $120M of rebate accruals to be paid in 2H 2026 (Aug 6) → in Q4 2026 (Nov 6) Watch

Why these signals: Kimmtrak is ▼ because net sales fell 11.8% from Q2 (our calculation)3, whatever the company’s adjusted year-on-year figure; brenetafusp is ⚠ because a planned trial and uncontrolled single-arm results don’t yet show an improvement.

Sources: Q2 2026 release, Q3 2026 release, 10-Q Q2 2026, 10-Q Q3 2026, TEBE-AM enrolment release.

Unresolved questions: why TEBE-AM moved; whether Q3’s adjusted growth holds in Q4; how far cash falls when the rebates are paid.

4. Buybacks vs real dilution (5 years)

Last updated Nov 12, 2026. Reflects the equity statements in the 10-K FY2023, 10-K FY2025 and 10-Q Q3 2026.

Dilution in one line: ordinary shares outstanding (voting and non-voting, including those held as ADSs) rose 17.7% from Dec 31, 2021 to Sep 30, 2026, about 3.5% a year compounded (our calculation)4. If you owned 1% of Immunocore at the end of 2021, you would have owned about 0.85% on Sep 30, 2026 without buying more (our calculation)5. None of the new shares were offset by buybacks. Our scale: High (over 3% a year).

Our rule of thumb: under 1% a year low, 1–3% moderate, over 3% high.

Change in shares outstanding, Dec 31, 2021 to Sep 30, 2026FY2022 +9.6%, FY2023 +3.4%, FY2024 +0.7%, FY2025 +1.2%, 9M 2026 +1.9%. Total +17.7% since Dec 31, 2021.0%+5%+10%+15%+20%FY2022: +9.6% in the period; +9.6% since Dec 31, 2021+9.6%FY2022FY2023: +3.4% in the period; +13.4% since Dec 31, 2021+3.4%FY2023FY2024: +0.7% in the period; +14.1% since Dec 31, 2021+0.7%FY2024FY2025: +1.2% in the period; +15.6% since Dec 31, 2021+1.2%FY20259M 2026 (part year): +1.9% in the period; +17.7% since Dec 31, 2021+1.9%9M 2026+17.7%since Dec 31, 2021

Change in the period Total since Dec 31, 2021 Part year

Shares outstanding at period end (all classes): 43.9M on Dec 31, 2021, 51.6M on Sep 30, 2026, +17.7% (our calculation). A bar below zero means the count fell (net buybacks).

All ordinary shares, voting and non-voting, including those held as ADSs (one ADS = one share), from the author's bridge (10-K and 10-Q equity statements); deferred shares (no voting or dividend rights) are excluded.

Period endShares outstandingChangeBuybacks (fiscal year)Stock-based pay (fiscal year)Stock pay as % of revenue
9M 2026 (Sep 30, 2026)51.6M+1.9%———
FY2025 (Dec 31, 2025)50.7M+1.2%—$38M9%
FY2024 (Dec 31, 2024)50.1M+0.7%—$34M11%
FY2023 (Dec 31, 2023)49.7M+3.4%—$32M13%
FY2022 (Dec 31, 2022)48.1M+9.6%—$33M19%
FY2021 (Dec 31, 2021)43.9M——$49M134%

Shares outstanding from the balance sheets in the company's 10-K and 10-Q filings; buybacks (cash spent) and stock-based pay from its 10-Ks, via SEC EDGAR.

Immunocore has never bought back stock. Most new shares came from the July 2022 share sale and from employee option exercises.

How we calculated this

Share basis: the headline and the bridge count all ordinary shares, voting and non-voting (734,397 non-voting at Dec 31, 2025), including those held as American depositary shares (one ADS = one ordinary share). The 5,793,501 deferred shares, which have no voting or dividend rights, are excluded throughout.

Bridge (millions of shares) 2022 2023 2024 2025 Nine months 2026 Total
Start of period 43.863 48.088 49.726 50.065 50.689 43.863
Options exercised 0.492 1.637 0.339 0.624 0.828 3.920
Restricted share units vested (rights to receive shares once vesting conditions are met) – – – – 0.119 0.119
Share sales for cash (private placement) 3.733 – – – – 3.733
Convertible notes converted – – – – – –
Acquisitions – – – – – –
Buybacks 0 0 0 0 0 0
End of period 48.088 49.726 50.065 50.689 51.636 51.636

Sources: 10-K FY2023 equity statement (2022–23); 10-K FY2025 (2024–25); 10-Q Q3 2026 (nine months 2026: 946,549 shares for “options exercised and units assigned”: 827,511 options exercised and 119,038 RSUs vested, per note 6).

Prices paid and received:

Period Shares bought back Average price paid Spent Shares sold for cash Average price received Raised Sources
2022 — — — 3.73M $37.50 (company’s offering price) about $140.0M gross (our calculation)6; $139.5M net 10-K FY2023, equity note
2023 — — — — — — 10-K FY2023 equity statement
2024 — — — — — — 10-K FY2025 equity statement
2025 — — — — — — 10-K FY2025 equity statement
2026 to date (Jan 1–Sep 30) — — — — — — 10-Q Q3 2026: no sales under the at-the-market programme

Immunocore has had no stock split since its 2021 listing, so figures are as reported. Proceeds from employee option exercises ($9.7M in 2022 to $20.9M in the first nine months of 2026) are excluded. The $402.5M of convertible notes (2024) raised cash but issued no shares. For reference, the stock closed at $31.65 on Nov 11, 2026 (reported, Stock Analysis).

Share awards, the convertible notes and the unused at-the-market programme could add shares later.

Possible further shares (Sep 30, 2026)
  • 10.71M options outstanding (average exercise price $30.99) and 0.91M unvested restricted share units (10-Q, note 6).
  • The convertible notes convert at 10.5601 ADSs per $1,000 (a conversion price of $94.70): about 4.25M shares (our calculation)7, or up to 5.95M after a “make-whole” adjustment (extra conversion shares after specified events such as a takeover) (10-K FY2025, note 7).
  • In the first nine months of 2026, a loss period, diluted and basic share counts were the same: 11,626,811 potential shares from options and RSUs, and the shares from the notes, were left out because including them would reduce the reported loss per share (10-Q, note 7).
  • An at-the-market programme with Jefferies (Sep 2022) allows sales of up to $250M of ADSs; none had been sold by Sep 30, 2026.
Stock-based pay 2022 2023 2024 2025 Nine months 2026
$M 32.9 32.5 34.2 37.7 25.4
% of total revenue (our calculation)8 19% 13% 11% 9% 8%

The 2026 figure is lower partly because forfeitures of share awards reduced Q1 selling, general and administrative (SG&A) expenses (Q1 2026 release).

Insider transactions: directors and officers were net sellers over the last 12 months, with no open-market purchases.

  • Net selling: 144,095 shares for about $5.6M (our calculation)9.
  • Largest seller by role: the then head of R&D, 130,923 shares (about $5.2M).
  • Under Rule 10b5-1 trading plans: 124,958 of those 130,923 shares; the other sellers sold only to cover taxes.
Insider transactions in detail
  • Period and method: Form 4 filings for Nov 12, 2025–Nov 11, 2026. The CEO, the chief HR officer and the chief accounting officer sold only to cover taxes on vesting share units, not under trading plans.
  • Former head of R&D David Berman sold 259,958 shares for about $9.8M (weighted prices $35.01–40.26) between Sep 10 and Dec 5, 2025, after exercising options with a $17.46 exercise price, under a Rule 10b5-1 trading plan (a prearranged selling plan) adopted May 9, 2025 (our calculation)9 (Form 4, Sep 12, Form 4, Dec 8). The plan covered up to 471,790 shares through Nov 20, 2026 and was terminated Feb 28, 2026 (10-Q Q1 2026). He announced his resignation on Jan 27, 2026. Form 144 notices of proposed sales for Mar–May 2026 cover a further 171,103 shares (about $5.1M at the stated market values; our calculation)9 (notices filed Mar 11, Apr 8, May 21 and May 22). A Form 144 reports a planned sale, not a completed one.
  • CEO Bahija Jallal sold 11,474 shares at a weighted $32.35 on Feb 18, 2026 to cover taxes on vesting restricted share units (Form 4). The Form 4s filed by directors and officers from Sep 2025 to Nov 11, 2026 report sales, option exercises, vesting and award grants, but no open-market purchases (EDGAR filing list; our review). Chief HR officer Tina St. Leger (1,000 shares), chief accounting officer John Goll (698) and Berman (5,965) made the same kind of tax sales on Feb 18, 2026 at a weighted $32.35 (Forms 4).
  • CEO options: the proxy reports 5,125,426 ordinary shares underlying options held by Dr Jallal that were exercisable within 60 days of Apr 2, 2026 (DEF 14A, Apr 16, 2026).
  • Director Siddharth Kaul adopted a trading plan for up to 26,198 shares on May 15, 2026, expiring May 17, 2027 (10-Q Q2 2026). Chief accounting officer John Goll adopted a Rule 10b5-1 plan for up to 42,044 shares on Sep 15, 2026, expiring Dec 31, 2027 (10-Q Q3 2026).

5. Profit vs cash (latest FY and TTM)

Last updated Nov 12, 2026. Reflects the 10-K FY2025 and the 10-Q Q3 2026. TTM means the 12 months to Sep 30, 2026.

Immunocore reports only figures under US accounting rules (GAAP); it publishes no adjusted earnings measure. Operating cash flow was $21.7M higher than net income over the last 12 months: a $32.1M net loss against $10.4M of operating cash outflow. Expected Q4 rebate payments will reduce cash.

$M FY2025 Trailing twelve months (TTM) to Sep 30, 2026 (our calculation)10
Net income (loss) −35.5 −32.1
Adjusted metric None reported None reported
Operating cash flow −10.7 −10.4
Capital spending −4.3 −7.8
Free cash flow (our calculation)11 −15.1 −18.2

Sorted by what each reconciling item does next:

Helps future profit or cash:

  • Receivables ($13.8M TTM; $88.0M at Sep 30, 2026, up from $74.0M at Dec 31, 2025): sales booked but not yet collected; the cash arrives when customers pay.
  • Prepayments ($13.8M TTM): the cash is already paid, so the matching expense later lowers profit without a new outflow.

Hurts future profit or cash:

  • Accrued expenses (+$12.2M TTM, mostly rebate and clinical accruals): cash kept for now that goes out when the rebates and bills are paid; the company expects to pay about $120M of rebate accruals in Q4 2026.
  • Stock-based pay ($37.7M in 2025; $33.8M TTM): a recurring cost that lowers reported profit; it is added back as a non-cash expense and shows up as new shares (dilution) instead (section 4).

One-off / no lasting effect:

  • Unrealised gains on marketable securities ($19.7M in 2025; $10.1M TTM): raise net income but bring in no cash unless the securities are sold.
  • A $14.8M deferred-tax charge reduced 2025 net income without using cash.
The raw reconciling items
  • Stock-based pay ($37.7M in 2025; $33.8M TTM, our calculation)12 is a non-cash expense added back.
  • Unrealised gains on marketable securities ($19.7M in 2025; $10.1M TTM) raise net income but bring in no cash.
  • Working capital: in the TTM, rising receivables took $13.8M and prepayments $13.8M, while accrued expenses (mostly rebate and clinical accruals) added $12.2M (our calculation)12. Receivables were $88.0M at Sep 30, 2026, up from $74.0M at Dec 31, 2025.
  • A $14.8M deferred-tax charge reduced 2025 net income without using cash.

Rebate accruals are the main estimate in the accounts, so they are worth a closer look:

  • Accruals for rebates, chargebacks and returns rose to $176.6M at Sep 30, 2026 from $132.8M at Dec 31, 2025; $41.6M of them are not due within 12 months (10-Q, note 3).
  • In the first nine months of 2026, provisions were $112.5M and credits and payments $68.7M (10-Q, note 3).
  • Prior-period rebate estimates added an $18.1M charge in 2024 and a $6.0M release in 2025, the latter “primarily related to European pricing negotiations” (10-K FY2025, note 3).
Tax losses

At Dec 31, 2025 Immunocore had tax-loss carryforwards of $525.5M in the UK and $73.6M in the US (10-K FY2025, note 12). These can reduce future taxable profit. Immunocore now holds a valuation allowance against the full amount of its net deferred tax assets (earlier: “a substantial amount”) (10-Q).

Operating spending ($M, disclosed) 2024 2025 Nine months 2026
Research and development (R&D) 222.2 274.9 209.8
Selling, general and administrative (SG&A) 155.8 165.4 122.2

Sources: 10-K FY2025 and 10-Q Q3 2026, income statements.

Funding: how long without new money? (our calculation; as of Sep 30, 2026, the latest filed balance sheet) Not within 5 years at the past rate and with known items: cash, cash equivalents and marketable securities of $901.3M covered about 49.5 years of trailing-12-month free cash outflow of $18.2M (our calculation)13, with no debt or convertible notes due within 24 months and no credit lines. The past year’s rate is flattered by rebates not yet paid: about $120M is due in Q4 2026, and total accrued revenue deductions were $176.6M at Sep 30.

Funding details
  • The run-out is a historical comparison, not a forecast (cash path below).
  • The company says its cash and marketable securities and anticipated Kimmtrak revenue will fund operating expenses and capital spending “for at least twelve months” from the 10-Q filing date, and that it intends “to consider additional financing opportunities when market terms are favorable” (10-Q).
  • This is based on past cash flow; spending plans can change it.

Financing items, sorted by what they do to the runway:

Extends the runway:

  • Committed undrawn financing: none; the 10-Q reports no lines of credit or guarantees.
  • Raises completed after Sep 30, 2026: none disclosed.

Shortens the runway:

  • About $120M of rebate payments expected in Q4 2026 (Q3 release); recurring, so not added to the cash path separately.
  • The $402.5M of 2.50% convertible notes mature on Feb 1, 2030 (nothing due within 24 months); the cash path assumes repayment in cash, with no conversion.

Conditional:

  • At-the-market share-sale programme: $250M with Jefferies, unused, so $250M remains. Uncommitted: it adds cash only if Immunocore chooses to sell shares.
  • From Feb 5, 2027 Immunocore may redeem the notes for cash if the ADS price has been at least 130% of the conversion price ($94.70) for 20 of 30 trading days (10-K FY2025, note 7); a redemption would use cash.
  • Holders can require repurchase of the notes for cash on a “fundamental change”, such as a takeover.
  • The Gates Foundation can sell its shares back to Immunocore after certain defaults on the HIV programme: no amount or date is disclosed.

Cash path (our calculation; an illustration, not a forecast):

At the past rate and with known items, cash would not fall below zero within 5 years; the company itself says only that its cash will last “at least twelve months” from Nov 6, 2026, and our path assumes flat spending.

Illustration, not a forecast.

Cash path: ending cash by quarter (illustration)Start $901M, Q4 2026 $897M, Q1 2027 $892M, Q2 2027 $888M, Q3 2027 $883M, Q4 2027 $879M, Q1 2028 $874M, Q2 2028 $869M, Q3 2028 $865M, Q4 2028 $860M, Q1 2029 $856M, Q2 2029 $851M, Q3 2029 $847M, Q4 2029 $842M, Q1 2030 $435M, Q2 2030 $431M, Q3 2030 $426M, Q4 2030 $421M, Q1 2031 $417M, Q2 2031 $412M, Q3 2031 $408M.$0M$250M$500M$750M$1.00BStart: $901MQ4 2026: $897MQ1 2027: $892MQ2 2027: $888MQ3 2027: $883MQ4 2027: $879MQ1 2028: $874MQ2 2028: $869MQ3 2028: $865MQ4 2028: $860MQ1 2029: $856MQ2 2029: $851MQ3 2029: $847MQ4 2029: $842MQ1 2030: $435MQ2 2030: $431MQ3 2030: $426MQ4 2030: $421MQ1 2031: $417MQ2 2031: $412MQ3 2031: $408MStartQ2 2027Q1 2028Q4 2028Q3 2029Q2 2030Q3 2031Q1 2030: known item −$403M (Convertible notes mature Feb 1, 2030: $402.5M principal, assumed repaid in cash because no conversion is assumed (10-Q))1
  1. 1 · Q1 2030 · Convertible notes mature Feb 1 −$403M

Ending cash (cash, equivalents and marketable securities) Known item

Quarter Starting cash Usual spending Known items Ending cash Sources / notes
Q4 2026 +901.3 −4.6 0.0 +896.7 About $120M of rebate payments are expected in Q4 2026 (Q3 release). They are not added separately: recurring rebates are already inside usual spending, and no one-off portion is disclosed
Q1 2027 +896.7 −4.6 0.0 +892.2
Q2 2027 +892.2 −4.6 0.0 +887.6
Q3 2027 +887.6 −4.6 0.0 +883.1
Q4 2027 +883.1 −4.6 0.0 +878.5
Q1 2028 +878.5 −4.6 0.0 +874.0
Q2 2028 +874.0 −4.6 0.0 +869.4
Q3 2028 +869.4 −4.6 0.0 +864.9
Q4 2028 +864.9 −4.6 0.0 +860.3
Q1 2029 +860.3 −4.6 0.0 +855.8
Q2 2029 +855.8 −4.6 0.0 +851.2
Q3 2029 +851.2 −4.6 0.0 +846.7
Q4 2029 +846.7 −4.6 0.0 +842.1
Q1 2030 +842.1 −4.6 −402.5 +435.1 Convertible notes mature Feb 1, 2030: $402.5M principal, assumed repaid in cash because no conversion is assumed (10-Q)
Q2 2030 +435.1 −4.6 0.0 +430.5
Q3 2030 +430.5 −4.6 0.0 +426.0
Q4 2030 +426.0 −4.6 0.0 +421.4
Q1 2031 +421.4 −4.6 0.0 +416.9
Q2 2031 +416.9 −4.6 0.0 +412.3
Q3 2031 +412.3 −4.6 0.0 +407.8

Amounts in $M.

Usual spending: about −$4.6M a quarter, held flat (our calculation)14.

No committed undrawn financing is disclosed, so there is no “financing that could extend the runway” table for Immunocore.

At the past rate and with known items, cash would not fall below zero within 5 years; the company itself says only that its cash will last “at least twelve months” from Nov 6, 2026, and our path assumes flat spending. Companies usually raise money well before that; quarters with less than a year of usual spending left are shaded.

Known items:

  • Feb 1, 2030: the $402.5M convertible notes mature; we assume repayment in cash, with no conversion (10-Q).
  • No disclosed, dated debt maturities, acquisition payments or completed raises after Sep 30, 2026.
How we calculated this
  • Usual spending is trailing-12-month free cash flow (−$18.2M, Q4 2025–Q3 2026) ÷ 4 ≈ −$4.6M a quarter (our calculation)14, held flat.
  • Starting cash is cash, cash equivalents and marketable securities at Sep 30, 2026 ($901.3M). Calculations use unrounded amounts ($901.298M; −$4.551M a quarter); displayed values are rounded to $0.1M.
  • One-off receipts: none in the TTM. There were no partner upfronts, milestones, settlements or asset sales, and collaboration revenue was nil in 2025 and the first nine months of 2026 (10-K FY2025, note 3; 10-Q). Sales of marketable securities are investing flows outside free cash flow.
  • One-off payments: none disclosed in the TTM. There were no licensing or acquisition upfronts paid, no settlements paid, and no other separately quantified non-recurring outflows; rebate credits and payments were $34.6M in the first nine months of 2026 (10-Q, note 3), and the roughly $120M of rebate payments expected in Q4 2026 falls after the TTM.
  • Both one-off tests are below the threshold of $3.6M (20% × $18.2M), so usual spending is not adjusted.

Not included:

  • The roughly $120M of rebate payments expected in Q4 2026 (Q3 release): recurring operating payments that past free cash flow already contains; the company has not split out a one-off amount. If they run above the past rate, the late-2026 balances would be lower than shown.
  • Note interest (2.50% a year, about $10.1M; our calculation)15 is paid in operating cash flow, so it is already inside usual spending.
  • Operating leases ($68.2M of total payments at Sep 30, 2026, plus a $3.0M lease starting in 2028 and a $1.9M lease that began on Oct 1, 2026) and $25.1M of non-cancellable manufacturing commitments, under the no-double-counting rule (10-Q, note 10).
  • Capital spending is inside usual spending: $7.8M TTM vs $4.3M in 2025. The company has quantified no capital plan.
  • The Gates Foundation’s right to sell its shares back to Immunocore after certain defaults on the HIV programme: no amount or date is disclosed.

6. Customer and contract exposure

Last updated Nov 12, 2026. Reflects the 10-K FY2025 and the 10-Q Q3 2026.

Immunocore sells Kimmtrak mainly through specialty distributors in the US and to hospitals and distributors in Europe, so a few unnamed customers account for most sales; the money ultimately comes from US government programmes and private insurers and from European national health systems.

Four unnamed customers each bought 17–23% of net product sales in 2025, so one customer’s order timing can shift a quarter’s sales.

Customers at 10% or more of net product sales (not named in the filings)
Customer 1Customer 2Customer 3Customer 420232023, Customer 1: 29% of net product sales2023, Customer 2: 26% of net product sales2023, Customer 3: 17% of net product sales2023, Customer 4: 16% of net product sales88%20242024, Customer 1: 29% of net product sales2024, Customer 2: 27% of net product sales2024, Customer 3: 18% of net product sales2024, Customer 4: 17% of net product sales91%20252025, Customer 1: 23% of net product sales2025, Customer 2: 23% of net product sales2025, Customer 3: 17% of net product sales2025, Customer 4: 18% of net product sales81%
Show the data
Label Customer 1 Customer 2 Customer 3 Customer 4 Unit
2023 29 26 17 16 % of net product sales
2024 29 27 18 17 % of net product sales
2025 23 23 17 18 % of net product sales

Chart source16. The filing lists the four in this order each year; they may not be the same companies across years.

Government payers, partners and suppliers also shape the exposure:

Payers, partners and suppliers
  • Government payers: US sales carry Medicaid rebates and 340B chargebacks (discounts to qualifying hospitals): chargeback provisions were $33.0M in the first nine months of 2026 (10-Q, note 3).
  • In Europe, each country sets the price: Germany renegotiated in 2025 after sales passed the €30M orphan-drug threshold, and France signed an agreement in 2025 covering retrospective and future prices, one element of which Immunocore disputes (10-K FY2025).
  • Partners: Medison is the exclusive distributor in Canada, Australia, New Zealand, Israel, Central and Eastern Europe and Latin America; Er-Kim covers Turkey, the Middle East, North Africa and the Commonwealth of Independent States. Under a revised agreement signed in November 2022, Medison paid a $5.0M non-refundable fee for exclusive rights to distribute Kimmtrak in South America; the contract runs for ten years from the first commercial sale there, which came in Q2 2025 (10-Q, note 3). Partnered revenue was $30.9M in the first nine months of 2026 vs $18.8M a year earlier (10-Q, note 3).
  • Suppliers: the 10-K names AGC Biologics A/S (Denmark) and Simtra Biopharma Solutions (Germany) as Kimmtrak’s contract manufacturers; Deutsche Post DHL Group provides storage, distribution, packaging and labelling in the Netherlands (10-K FY2025).
Key agreement Signed Terms Note
Convertible notes Feb 2024 $402.5M, 2.50%, due Feb 1, 2030; conversion price $94.70 Holders can require repurchase for cash on a “fundamental change”, such as a takeover (10-K FY2025, note 7)
BMS clinical supply Feb 2024 BMS supplies nivolumab for PRISM-MEL-301; no payments Immunocore sponsors and funds the trial (10-K FY2025)
EORTC (ATOM trial) 2023 EORTC sponsors and runs the adjuvant uveal melanoma trial First patient randomised Dec 2024 (10-K FY2025)
Gates Foundation — Immunocore must develop drugs for agreed neglected diseases (currently HIV) at affordable prices in developing countries After certain defaults, the Foundation can sell its shares or require Immunocore to buy them back (10-Q, note 10)
Jefferies at-the-market programme Sep 2022 Up to $250M of ADSs Unused at Sep 30, 2026

Other items: Immunocore says it is not currently a party to any material legal proceedings; in October 2026 it signed a 10-year premises lease, starting Oct 1, 2026, with $1.9M of minimum payments (10-Q, note 10).

7. Immunocore’s strategy for long-term growth

Last updated Nov 12, 2026. Reflects the 10-K FY2025, the 10-Q for Q3 2026 and the Q3 release (Nov 6, 2026).

Immunocore is trying to take Kimmtrak beyond one rare cancer and to turn its platform into a second product; the new uses depend on Phase 3 trials that have not read out yet.

  • Pressures on the core business: Kimmtrak is its only marketed drug, in a rare cancer. Analysts at Jefferies argued in March, when they downgraded the stock to Hold, that Kimmtrak was nearing peak sales (reported, Investing.com). Competition spans Kimmtrak’s current uveal melanoma use and its proposed skin melanoma expansion: IDEAYA has filed for approval of its own uveal melanoma combination (IDEAYA, Nov 3), and Replimune’s newly approved TUDRIQEV reached its first patients with advanced melanoma in October (Replimune, Oct 28).
  • The strategy in management’s words: three “key growth areas” for Kimmtrak: “continued US community and global market penetration” in metastatic uveal melanoma, previously treated advanced skin (cutaneous) melanoma, and adjuvant uveal melanoma (treatment after surgery or radiotherapy to lower the risk of the cancer returning) (Q3 release). The steps so far:
    • TEBE-AM, the Phase 3 trial in previously treated skin melanoma, is fully enrolled with 540 patients; topline overall survival data are expected in Q2 2027;
    • ATOM, a Phase 3 trial in adjuvant uveal melanoma run by the EORTC, is enrolling;
    • programmes targeting PRAME, a protein found on many cancer cells: brenetafusp with nivolumab in the PRISM-MEL-301 Phase 3 trial in first-line skin melanoma, and DUET-UVEAL, a planned randomized Phase 2/3 trial of brenetafusp with Kimmtrak in metastatic uveal melanoma;
    • further back: an HIV candidate (IMC-M113V) and two autoimmune candidates; the first person with type 1 diabetes has been dosed with IMC-S118AI.
  • How well it is working, in numbers:
    • Kimmtrak net sales of $324.8M in the first nine months of 2026, +10%;
    • company-estimated populations: up to 4,000 HLA-A*02:01-positive patients with previously treated advanced skin melanoma and up to 1,200 high-risk adjuvant uveal melanoma patients in the US and Europe, and about 10,000 first-line skin melanoma patients for PRISM-MEL-301 (Q3 release);
    • targets: Immunocore has given no sales targets.
  • What to watch: see section 8.

8. What to watch

Last updated Nov 12, 2026. Reflects the 10-Q Q3 2026 and the Q3 release (Nov 6, 2026).

Date Item Source
Q4 2026 Payment of about $120M of sales-related rebate accruals Q3 release
Later in 2026 Brenetafusp data from the ovarian and lung cancer cohorts of the Phase 1/2 trial, at a medical conference Q3 release
By year-end 2026 Clinical trial application (CTA) or investigational new drug (IND) application for IMC-U120AI (atopic dermatitis and other skin diseases) Q3 release
Early 2027 Higher-dose HIV (IMC-M113V) data Q3 release
From Feb 5, 2027 Immunocore may redeem the convertible notes if the ADS price has been at least 130% of $94.70 for 20 of 30 trading days 10-K FY2025
Q2 2027 TEBE-AM topline overall survival data (event-driven) Q3 release
Oct 2027 (registry estimate) PRISM-MEL-301 primary completion (brenetafusp with nivolumab in first-line skin melanoma; 680 patients) ClinicalTrials.gov NCT06112314
Not dated Start of DUET-UVEAL, the randomized Phase 2/3 trial of Kimmtrak with brenetafusp Q3 release
Additional dates
Date Item Source
Not dated First data for IMC-P115C: promised for 2H 2026 in August; the Q3 release says only that enrolment continues Q2 2026 release; Q3 release
Mar 2028 (registry estimate) TEBE-AM final primary completion ClinicalTrials.gov NCT05549297
Feb 1, 2030 $402.5M convertible notes mature 10-Q Q3 2026

Valuation at each update

At the close used for each update, from the filings available then. Frozen when the update is published; never revised.

UpdateCloseMarket valueEVP/SEV/salesP/EP/FCFRevenue growthFCF marginNet cash (debt)Basis
Oct 28, 2026$30.98 (Oct 23)$1.6B$1.1B3.7×2.6×n/mn/m+21%−10%$486M12 months to Jun 30, 2026
Nov 12, 2026$31.65 (Nov 11)$1.6B$1.1B3.8×2.6×n/mn/m+13%−4%$507M12 months to Sep 30, 2026

Our calculation from each update's filings (latest at the newest update: 10-Q for the quarter to Sep 30, 2026, filed Nov 6, 2026); not investment advice. n/m = not meaningful (e.g. negative earnings). Hover a heading for its definition. Oct 28, 2026 row: Updated Nov 12, 2026: debt now includes the $402.5M of convertible notes due 2030, at their $394.2M carrying value on Jun 30, 2026 (10-Q Q2 2026), which our data fetch missed; net cash is $486.0M (was $880.2M) and enterprise value $1.11B (was $0.71B), so EV/sales is 2.6 (was 1.7). Price, date and market value are unchanged. Oct 28, 2026 price: the Long View's stated close (Stock Analysis). Nov 12, 2026 price: official close, Yahoo Finance, CNBC.

Notes and calculations

  1. Shares of 2025 net sales: US $257.0M ÷ $400.0M = 64.3%; Europe $131.4M ÷ $400.0M = 32.9%; international $11.6M ÷ $400.0M = 2.9%. ↩

  2. Nine-month 2026 cost of revenue $2.198M ÷ net sales $324.826M = 0.7%. ↩

  3. Q3 2026 sales $102.2M ÷ Q2 2026 sales $115.9M − 1 = −11.8%, about −12%. ↩ ↩2

  4. Total change = 51,635,820 ÷ 43,862,850 − 1 = 17.7%. Annual rate = (51,635,820 ÷ 43,862,850)^(1 ÷ 4.75) − 1 = 3.5%, where 4.75 years = Dec 31, 2021 to Sep 30, 2026. ↩

  5. 1% × 43,862,850 ÷ 51,635,820 = 0.849%. ↩

  6. Gross proceeds = 3,733,333 shares × $37.50 = $140.0M. The $139.5M net figure is as disclosed. ↩

  7. $402,500,000 ÷ $1,000 × 10.5601 = 4,250,440 ADSs. ↩

  8. Stock pay as % of revenue = stock-based compensation ÷ total revenue. Revenue: $174.4M (2022), $249.4M (2023), $310.2M (2024), $400.0M (2025), $324.8M (nine months 2026), including small collaboration revenue in 2022–24. ↩

  9. Berman’s sales: sum of the sale lines in six Form 4s filed Sep 12–Dec 8, 2025 (full list on EDGAR): 259,958 shares, about $9.83M (shares × weighted price per line). Form 144 notices: 11,832 + 25,000 + 65,000 + 69,271 = 171,103 shares; aggregate market values $0.39M + $0.80M + $1.89M + $2.04M = about $5.12M. Last-12-month Form 4 sales (Nov 12, 2025–Nov 11, 2026): Berman under his plan 18,120 + 74,925 + 31,913 = 124,958 shares, $0.725M + $3.006M + $1.285M = $5.016M (Forms 4 filed Nov 26, Dec 1 and Dec 8, 2025); tax sales on Feb 18, 2026 by Jallal 11,474, Berman 5,965, St. Leger 1,000 and Goll 698 = 19,137 shares × $32.35 = $0.619M. Total 144,095 shares, about $5.63M. Purchases: none (the other Form 4 entries are option exercises, vesting and award grants). Berman’s Form 144 sales after he left in Feb 2026 are not on Form 4 and are not counted. ↩ ↩2 ↩3

  10. TTM = FY2025 − nine months 2025 + nine months 2026. Net income: −$35.514M − (−$5.454M) + (−$2.059M) = −$32.119M. Operating cash flow: −$10.712M − $21.943M + $22.243M = −$10.412M. Capital spending: $4.340M − $1.460M + $4.913M = $7.793M (10-K FY2025 and 10-Q Q3 2026 cash-flow statements). ↩

  11. Free cash flow = operating cash flow − capital spending: FY2025 −$10.712M − $4.340M = −$15.052M; TTM −$10.412M − $7.793M = −$18.205M. ↩

  12. TTM items = FY2025 − nine months 2025 + nine months 2026. Stock-based pay: $37.698M − $29.359M + $25.436M = $33.775M. Unrealised gains: $19.728M − $15.224M + $5.609M = $10.113M. Receivables: −$7.336M − (−$9.330M) + (−$15.803M) = −$13.809M. Prepayments: −$6.740M − (−$5.724M) + (−$12.791M) = −$13.807M. Accrued expenses: $15.889M − $37.920M + $34.259M = $12.228M. ↩ ↩2

  13. Cash, cash equivalents and marketable securities = $512.245M + $389.053M = $901.298M. Runway = $901.298M ÷ $18.205M = 49.5 years. ↩

  14. Usual spending is the past year’s free cash flow divided by four: −$18.205M ÷ 4 = −$4.551M a quarter, held flat. ↩ ↩2

  15. 2.50% × $402.5M = $10.06M a year. ↩

  16. Chart source: 10-K FY2025, note 3. Four customers also held 20%, 18%, 20% and 16% of receivables at Dec 31, 2025. ↩

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.

About Immunocore: Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)